Hansoh Pharmaceutical Achieves Multiple Breakthroughs in Innovative Drug Development with Key Milestones in October

　　【Pharmaceutical Network Enterprise News] Amid the surging wave of China's innovative drug industry development, Hansoh Pharma has established a strong foothold and built advantages through profound R&D accumulation and strategic planning. From impressive sales figures to recent waves of positive news, the company is making continuous progress with robust momentum in both domestic and international innovative drug markets.
 

From the performance perspective, Hansoh Pharma's innovative drug business has become the core growth engine. According to the company’s semi-annual report, the sales revenue of its innovative drugs and collaborative products reached 6.145 billion RMB in the first half of this year, increasing by 22.1% year-on-year, accounting for up to 82.7% of total revenue. Currently, the company generates sales revenue from 7 innovative drugs produced in China, which widely cover multiple therapeutic areas. This solid product portfolio lays a firm foundation for its sustainable development.
 

Entering October, Hansoh Pharma has consecutively received several pieces of good news. For instance, on October 23, the website of the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) showed that the marketing application for HS-10365 capsules, a Class 1 new drug independently developed by Hansoh Pharma, has been accepted. It is speculated that the drug's indication is RET fusion-positive non-small cell lung cancer (NSCLC). This submission marks an important advancement for Hansoh Pharma in the field of precision treatment.
 

Data shows that HS-10365 is a highly active and highly selective RET tyrosine kinase inhibitor. Previous Phase I clinical research results indicate that the drug demonstrates encouraging anti-tumor activity and durable responses in patients with RET fusion-positive non-small cell lung cancer (NSCLC), with controllable safety and favorable PK characteristics. Hansoh Pharma is currently conducting registrational clinical studies on the efficacy and safety of HS-10365 as a first-line treatment for RET fusion-positive locally advanced or metastatic non-small cell lung cancer. Compared with traditional chemotherapy drugs, HS-10365 exhibits higher target selectivity, which means it may offer better safety while exerting its anti-tumor effects. As an important product in Hansoh Pharma’s R&D pipeline, HS-10365 is expected to bring new growth opportunities for the company in the future.
 

While domestic R&D is proceeding steadily, Hansoh Pharma has also achieved a major breakthrough in the overseas expansion of innovative drugs. On October 17, Hansoh Pharma announced that it had signed a licensing agreement with Roche for HS-20110, receiving an $80 million upfront payment, up to $1.45 billion in clinical development, regulatory and sales milestone payments, as well as tiered royalties based on a certain percentage of future net sales.
 

Data shows that HS-20110 is an investigational CDH17-targeted antibody-drug conjugate (ADC) currently in global Phase I clinical trials in China and the United States for the treatment of colorectal cancer and other solid tumors. It is reported that CDH17, as a transmembrane adhesion molecule, is highly restricted to the basolateral membrane expression in normal intestinal epithelium, while showing significant overexpression in gastrointestinal malignancies such as colorectal cancer, gastric cancer, and pancreatic cancer. This unique expression pattern makes CDH17 an ideal target for ADC drug development.
 

Industry insiders pointed out that this cooperation is another important example of Chinese innovative pharmaceutical companies' R&D capabilities in the ADC field being recognized by international pharmaceutical companies. Combined with Hansoh Pharma's previous authorization of B7H3 and B7H4 ADCs to GSK, it shows that Hansoh has established a sustainable ADC technology platform, which is of greater strategic value than the success of a single product.
 

It is reported that, prior to this collaboration, Hansoh Pharma had already reached license-out collaborations totaling over 7 billion US dollars with GSK, Merck, and Regeneron around B7-H3 targeted ADC (HS-20093), B7-H4 targeted ADC (HS-20089), GLP-1/GIP dual receptor agonist (HS-20094), and oral small molecule GLP-1 (HS-10535).
 

A series of high-value license-out collaborations have not only brought substantial financial returns to Hansoh Pharma, but more importantly, through cooperation with international teams, the company can leverage their R&D resources, clinical experience, and global sales networks to accelerate the global development and commercialization process of innovative drugs. At the same time, it has also enhanced its own reputation and influence in the international innovative drug market.
 

From the in-depth cultivation of products in the Chinese market to the technology export on the global stage, Hansoh Pharma is continuously breaking boundaries in the innovative drug field with a clear strategic path. In the future, as more innovative drugs enter the late clinical stages or even receive approval for marketing, and with the continuous deepening of international cooperation, this Chinese innovative pharmaceutical company is expected to occupy a more significant position in global competition, contributing more to the high-quality development and internationalization process of China's innovative drug industry.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice for any person.